Skin disorders
23 results
Applied filters
Doxycycline and metronidazole for human and animal bites
27 November 2025SPS PGD templates for supply of doxycycline and metronidazole for the prophylaxis of human and animal bites in specified patient groups
Co-amoxiclav for human and animal bites
27 November 2025SPS PGD template for supply of co-amoxiclav for the prophylaxis of human and animal bites in specified patient groups.
Permethrin for scabies
27 November 2025SPS PGD template for supply of permethrin for the treatment of scabies in specified patient groups.
Malathion for scabies
27 November 2025SPS PGD template for supply of malathion for the treatment of scabies in specified patient groups.
The licence and supporting evidence for omalizumab biosimilar
21 January 2026One omalizumab biosimilar is currently available: Omlyco. Learn about the licensed indications, available preparations, supporting evidence and key differences.
Preparing to use omalizumab biosimilar
20 January 2026One omalizumab biosimilar (Omlyclo) is available and other biosimilars are in development. We offer general information and implementation advice.
Using potassium permanganate for skin conditions or wound care
4 April 2025Potassium permanganate is a chemical product. We review the evidence for using it in wound care and highlight the risk of severe harm associated with wrong use.
Good governance when implementing ustekinumab biosimilar
29 July 2025Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
29 July 2025Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use ustekinumab biosimilar
29 July 2025Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.